Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN)
CUSIP: 23255M204
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 3,367,000
- Total 13F shares
- 1,051,710
- Share change
- -18,544
- Total reported value
- $2,411,691
- Price per share
- $2.30
- Number of holders
- 17
- Value change
- -$42,676
- Number of buys
- 7
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 23255M204?
CUSIP 23255M204 identifies CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 23255M204:
Top shareholders of CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Slate Path Capital LP |
13F
|
Company |
11%
|
357,880
|
$1,145,216 | — | 31 Mar 2024 | |
| MFN Partners Management, LP |
13F
|
Company |
5%
|
169,460
|
$542,272 | — | 31 Mar 2024 | |
| TYNDALL CAPITAL PARTNERS L P |
13F
|
Company |
4.9%
|
164,777
|
$527,286 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
4.8%
|
162,327
|
$519,447 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
4.1%
|
138,955
|
$444,656 | — | 31 Mar 2024 | |
| Terrance McGuire |
3/4/5
|
Director |
—
class O/S missing
|
42,010
|
$142,624 | — | 30 Nov 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.95%
|
32,082
|
$102,694 | — | 31 Mar 2024 | |
| Errol B. Desouza |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$101,850 | — | 30 Nov 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.7%
|
23,490
|
$75,168 | — | 31 Mar 2024 | |
| Dina Katabi |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| Steven Hyman |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.51%
|
17,169
|
$54,941 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
2,524
|
$8,077 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
649
|
$2,077 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
540
|
$1,728 | — | 31 Mar 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
352
|
$1,000 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
33
|
$106 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
15
|
$48 | — | 31 Mar 2024 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
1
|
$3 | — | 31 Mar 2024 | |
| Andreas Busch |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Anjeza Gjino |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Cheryl Gault |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| George H. Conrades |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Marsha Fanucci |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Michael Mendelsohn |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Ole Isacson |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Stephanie Lovell |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Kevin Churchwell |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 24 Jun 2021 |
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q2 2024
As of 30 Jun 2024,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,051,710 shares.
The largest 10 holders included
Slate Path Capital LP, MFN Partners Management, LP, TYNDALL CAPITAL PARTNERS L P, FMR LLC, Artal Group S.A., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock Inc., UBS Group AG, and Tower Research Capital LLC (TRC).
This page lists
17
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
15
Q2 2024 holders
17
Holder diff
2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.